Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Chinese Chip Stocks Jump as Apple Reportedly Tests CXMT Memory Chips for China Devices 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
AUSTIN, Texas, May 03, 2018 -- Vermillion, Inc. (Nasdaq:VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report its first quarter ended March 31, 2018 financial results on Monday, May 14, 2018, followed by an investor conference call and webcast at 4:30 p.m. Eastern Time.
| Monday, May 14th @ 4:30pm Eastern Time | |||
| Domestic: | 800-239-9838 | ||
| International: | 323-794-2551 | ||
| Conference ID: | 5200441 | ||
| Webcast: | http://public.viavid.com/index.php?id=129615 | ||
| Replays, Available through May 28: | |||
| Domestic: | 844-512-2921 | ||
| International: | 412-317-6671 | ||
| Replay PIN: | 5200441 | ||
About Vermillion
Vermillion, along with its prestigious scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. The company's initial in vitro diagnostic test, OVA1® (MIA), was the first FDA cleared, protein-based In Vitro Diagnostic Multivariate Index Assay, and represented a new class of software-based liquid biopsy in vitro diagnostics. In March 2016, Vermillion received FDA clearance for Overa™, a Multivariate Index Assay 2nd Generation (MIA2G) test with significantly improved specificity and ease of use. Vermillion, Inc.’s tests are intended to characterize and stage disease, and to help guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in monitoring response to therapy.
Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
Tel 617-535-7742
[email protected]
